注射用红花黄色素联合GP方案治疗中晚期乳腺癌的临床观察
x

请在关注微信后,向客服人员索取文件

篇名: 注射用红花黄色素联合GP方案治疗中晚期乳腺癌的临床观察
TITLE:
摘要: 目的:考察红花提取物联合GP(吉西他滨+顺铂)方案对中晚期乳腺癌的临床疗效及安全性。方法:98例中晚期乳腺癌患者按照随机数字表法分成研究组(A组)和对照组(B组),各49例。B组患者仅予以GP方案化疗,3周为1个疗程;A组患者采用GP方案化疗联合注射用红花黄色素100 mg静脉滴注,qd,2周为1个疗程。比较两组患者的临床疗效和治疗前后肿瘤坏死因子α(TNF-α)、血管内皮生长因子(VEGF)、基质金属蛋白酶2(MMP-2)、MMP-9等指标的变化差异,以及不良反应发生情况。结果:A组患者总有效率为83.7%,显著高于B组的63.3%,差异具有统计学意义(P<0.05)。治疗后,两组患者TNF-α、VEGF、MMP-2及MMP-9等指标均较治疗前显著降低,差异具有统计学意义(P<0.05),且A组降幅大于B组,差异具有统计学意义(P<0.05)。两组患者除恶心呕吐发生率比较差异无统计学意义外,A组患者白细胞计数降低、贫血、脱发、食欲下降、肝功能异常、腹泻等不良反应发生率均显著低于B组,差异具有统计学意义(P<0.05)。结论:对中晚期乳腺癌患者予以注射用红花黄色素联合GP化疗方案,可发挥红花提取物抗炎、促进血流灌注、抑制新生血管生成等功效,有效抑制病情发展、减轻化疗毒副反应。
ABSTRACT: OBJECTIVE: To investigate the clinical efficacy and safety of Safflower yellow for injection combined with GP (gemcitabine+cisplatin) regimen for middle-advanced breast cancer. METHODS: 98 patients with middle-advanced breast cancer were randomly divided into study group (group A) and control group (group B), with 49 cases in each group. Group B was only treated with GP regimen, and its treatment course lasted for 3 weeks. Group A was treated with GP regimen combined with intravenous dripping of Safflower yellow for injection 100 mg, qd, and the treatment course lasted for 2 weeks. Clinical efficacy, the variance of TNF-α, VEGF, MMP-2, MMP-9 and other indexes were compared between 2 groups before and after treatment, and the occurrence of ADR were compared. RESULTS: The total effective rate of group A was 83.7%, which was significantly higher than 63.3% of group B, with statistical significance (P<0.05). After treatment, TNF-α, VEGF, MMP-2, MMP-9 and other indexes were significantly lower than before, with statistical significance (P<0.05); the decrease of group A was more significant than those of group B, with statistical significance (P<0.05). Except that there was no statistically significant difference in the incidence of nausea and vomiting between 2 groups, the incidence of ADR as white blood cell count decreasing, anemia, hair loss, loss of appetite, abnormal liver function and diarrhea in group A were significantly lower than those in group B, with statistical significance (P<0.05). CONCLUSIONS: For patients with middle-advanced breast cancer, to adopt Safflower yellow for injection combined with GP regimen can bring the effects of Safflower yellow for injection, such as anti-inflammation, improving blood infusion and inhibiting the generation of new vessel. And it can effectively inhibit the development of disease and alleviate toxic and side effects of chemotherapy.
期刊: 2016年第27卷第2期
作者: 刘冉
AUTHORS: LIU Ran
关键字: 注射用红花黄色素;GP化疗方案;中晚期乳腺癌;疗效
KEYWORDS: Safflower yellow for injection; GP chemotherapy regimen; Middle-advanced stage breast cancer; Curative efficacy
阅读数: 276 次
本月下载数: 3 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!